Found 384 Enz. Inhib. hit(s) with all data for entry = 207 
Affinity DataIC50: 0.940nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 0.960nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.20nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.20nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.90nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 3.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 4.70nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 5.70nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 7.60nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 23nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 24nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 24nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 25nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 25nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 26nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 26nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 27nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 27nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 27nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 28nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 28nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 28nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 29nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 38nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 49nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 156nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.03E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.32E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.34E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.36E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.38E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.63E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: 2.70E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: >3.00E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: >3.00E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
Affinity DataIC50: >3.00E+3nMT: 2°CAssay Description:The ability of the compounds of the current invention to inhibit platelet aggregation induced by gamma-thrombin was tested in a 96-well microplate ag...More data for this Ligand-Target Pair
